Literature DB >> 34211779

Evaluation of two-dimensional electronic portal imaging device using integrated images during volumetric modulated arc therapy for prostate cancer.

Shoki Inui1,2, Yoshihiro Ueda1, Shunsuke Ono1, Shingo Ohira1, Masaru Isono1, Yuya Nitta1, Hikari Ueda1, Masayoshi Miyazaki1, Masahiko Koizumi2, Teruki Teshima1.   

Abstract

BACKGROUND: The aim of the study was to evaluate analysis criteria for the identification of the presence of rectal gas during volumetric modulated arc therapy (VMAT) for prostate cancer patients by using electronic portal imaging device (EPID)-based in vivo dosimetry (IVD).
MATERIALS AND METHODS: All measurements were performed by determining the cumulative EPID images in an integrated acquisition mode and analyzed using PerFRACTION commercial software. Systematic setup errors were simulated by moving the anthropomorphic phantom in each translational and rotational direction. The inhomogeneity regions were also simulated by the I'mRT phantom attached to the Quasar phantom. The presence of small and large air cavities (12 and 48 cm3) was controlled by moving the Quasar phantom in several timings during VMAT. Sixteen prostate cancer patients received EPID-based IVD during VMAT.
RESULTS: In the phantom study, no systematic setup error was detected in the range that can happen in clinical (< 5-mm and < 3 degree). The pass rate of 2% dose difference (DD2%) in small and large air cavities was 98.74% and 79.05%, respectively, in the appearance of the air cavity after irradiation three quarter times. In the clinical study, some fractions caused a sharp decline in the DD2% pass rate. The proportion for DD2% < 90% was 13.4% of all fractions. Rectal gas was confirmed in 11.0% of fractions by acquiring kilo-voltage X-ray images after the treatment.
CONCLUSIONS: Our results suggest that analysis criteria of 2% dose difference in EPID-based IVD was a suitable method for identification of rectal gas during VMAT for prostate cancer patients.
© 2021 Greater Poland Cancer Centre.

Entities:  

Keywords:  electronic portal imaging device (EPID); in vivo dosimetry (IVD); patient-specific quality assurance (QA); prostate cancer; rectal gas

Year:  2021        PMID: 34211779      PMCID: PMC8241304          DOI: 10.5603/RPOR.a2021.0041

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  25 in total

1.  In vivo dosimetry for prostate cancer patients using an electronic portal imaging device (EPID); demonstration of internal organ motion.

Authors:  M Kroonwijk; K L Pasma; S Quint; P C Koper; A G Visser; B J Heijmen
Journal:  Radiother Oncol       Date:  1998-11       Impact factor: 6.280

2.  Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use?

Authors:  Valérie Fonteyne; Piet Ost; Frank Vanpachtenbeke; Roos Colman; Simin Sadeghi; Geert Villeirs; Karel Decaestecker; Gert De Meerleer
Journal:  Radiother Oncol       Date:  2014-11-28       Impact factor: 6.280

3.  A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers.

Authors:  Alan M Nichol; Kristy K Brock; Gina A Lockwood; Douglas J Moseley; Tara Rosewall; Padraig R Warde; Charles N Catton; David A Jaffray
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-02       Impact factor: 7.038

4.  Toward planning target volume margin reduction for the prostate using intrafraction motion correction with online kV imaging and automatic detection of implanted gold seeds.

Authors:  Tezontl Rosario; Lineke van der Weide; Marjan Admiraal; Maartje Piet; Ben Slotman; Johan Cuijpers
Journal:  Pract Radiat Oncol       Date:  2018-04-25

5.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

6.  Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

Authors:  Pirus Ghadjar; George N Thalmann
Journal:  BJU Int       Date:  2012-11       Impact factor: 5.588

7.  Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins.

Authors:  J A Connolly; K Shinohara; J C Presti; P R Carroll
Journal:  Urology       Date:  1996-02       Impact factor: 2.649

8.  A Simple Method for 2-D In Vivo Dosimetry by Portal Imaging.

Authors:  Stefano Peca; Derek Wilson Brown; Wendy Lani Smith
Journal:  Technol Cancer Res Treat       Date:  2017-06-06

9.  In vivo Portal Imaging Dosimetry Identifies Delivery Errors in Rectal Cancer Radiotherapy on the Belly Board Device.

Authors:  Stefano Peca; Richie Siddhartha Sinha; Derek Wilson Brown; Wendy Lani Smith
Journal:  Technol Cancer Res Treat       Date:  2017-06-06

10.  Sensitivity study of an automated system for daily patient QA using EPID exit dose images.

Authors:  Audrey H Zhuang; Arthur J Olch
Journal:  J Appl Clin Med Phys       Date:  2018-03-06       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.